XML 40 R23.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Supplemental Guarantor Financial Information | 12 Months Ended
--- | ---
Dec. 31, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract] |
Supplemental Guarantor Financial Information | Supplemental Guarantor Financial Information In October 2014, Halyard Health, Inc. (referred to below as “Parent”) issued the Notes (described in Note 8, “Debt”). The Notes are guaranteed, jointly and severally by each of our domestic subsidiaries that guarantees the Senior Credit Facilities (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions as defined in the Indenture dated October 17, 2014. Each Guarantor Subsidiary is directly or indirectly 100%-owned by Halyard Health, Inc. Each of the guarantees of the Notes is a general unsecured obligation of each Guarantor and ranks equally in right of payment with all existing and future indebtedness and all other obligations (except subordinated indebtedness) of each Guarantor. The following condensed consolidating balance sheets as of December 31, 2017 and 2016 and the condensed consolidating statements of income and cash flows for the years ended December 31, 2017, 2016 and 2015 provide condensed consolidating financial information for Halyard Health, Inc. (“Parent”), the Guarantor Subsidiaries on a combined basis, the Non-Guarantor Subsidiaries on a combined basis and the Parent and its subsidiaries on a consolidating basis. The Parent and the Guarantor Subsidiaries use the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation. Eliminating entries in the following condensed consolidating financial information represent adjustments to (i) eliminate intercompany transactions between or among the Parent, the Guarantor Subsidiaries and the Non-Guarantor Subsidiaries and (ii) eliminate the investments in subsidiaries. HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 679.2 |  |  | $ | 306.9 |  |  | $ | (374.5 | ) |  | $ | 611.6 |
Cost of products sold | — |  |  | 385.7 |  |  | 263.5 |  |  | (374.5 | ) |  | 274.7 |
Gross Profit | — |  |  | 293.5 |  |  | 43.4 |  |  | — |  |  | 336.9 |
Research and development expenses | — |  |  | 38.2 |  |  | — |  |  | — |  |  | 38.2 |
Selling and general expenses | 29.9 |  |  | 249.7 |  |  | 42.1 |  |  | — |  |  | 321.7 |
Other expense (income), net | 0.7 |  |  | 34.5 |  |  | (15.1 | ) |  | — |  |  | 20.1 |
Operating (Loss) Profit | (30.6 | ) |  | (28.9 | ) |  | 16.4 |  |  | — |  |  | (43.1 | )
Interest income | 0.9 |  |  | 0.1 |  |  | 4.5 |  |  | (3.0 | ) |  | 2.5 |
Interest expense | (32.3 | ) |  | (2.2 | ) |  | (0.1 | ) |  | 3.0 |  |  | (31.6 | )
(Loss) Income Before Income Taxes | (62.0 | ) |  | (31.0 | ) |  | 20.8 |  |  | — |  |  | (72.2 | )
Income tax benefit (provision) | 20.0 |  |  | 23.2 |  |  | (3.1 | ) |  | — |  |  | 40.1 |
Equity in earnings of consolidated subsidiaries | 125.1 |  |  | 32.6 |  |  | — |  |  | (157.7 | ) |  | — |
Net Income (Loss) from Continuing Operations | 83.1 |  |  | 24.8 |  |  | 17.7 |  |  | (157.7 | ) |  | (32.1 | )
(Loss) Income on discontinued operations, net of tax | (3.8 | ) |  | 86.0 |  |  | 29.2 |  |  | — |  |  | 111.4 |
Net Income (Loss) | 79.3 |  |  | 110.8 |  |  | 46.9 |  |  | (157.7 | ) |  | 79.3 |
Total other comprehensive income (loss), net of tax | 18.8 |  |  | 13.1 |  |  | 18.3 |  |  | (31.4 | ) |  | 18.8 |
Comprehensive Income (Loss) | $ | 98.1 |  |  | $ | 123.9 |  |  | $ | 65.2 |  |  | $ | (189.1 | ) |  | $ | 98.1 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 625.4 |  |  | $ | 250.0 |  |  | $ | (309.2 | ) |  | $ | 566.2 |
Cost of products sold | — |  |  | 356.7 |  |  | 221.5 |  |  | (309.2 | ) |  | 269.0 |
Gross Profit | — |  |  | 268.7 |  |  | 28.5 |  |  | — |  |  | 297.2 |
Research and development expenses | — |  |  | 38.0 |  |  | 0.4 |  |  | — |  |  | 38.4 |
Selling and general expenses | 37.2 |  |  | 274.2 |  |  | 34.8 |  |  | — |  |  | 346.2 |
Other (income) expense, net | (0.8 | ) |  | 36.4 |  |  | (17.5 | ) |  | 1.6 |  |  | 19.7 |
Operating (Loss) Profit | (36.4 | ) |  | (79.9 | ) |  | 10.8 |  |  | (1.6 | ) |  | (107.1 | )
Interest income | 0.3 |  |  | 0.1 |  |  | 2.5 |  |  | (2.3 | ) |  | 0.6 |
Interest expense | (33.1 | ) |  | (1.7 | ) |  | (0.2 | ) |  | 2.3 |  |  | (32.7 | )
(Loss) Income Before Income Taxes | (69.2 | ) |  | (81.5 | ) |  | 13.1 |  |  | (1.6 | ) |  | (139.2 | )
Income tax benefit (provision) | 25.5 |  |  | 33.9 |  |  | (3.5 | ) |  | — |  |  | 55.9 |
Equity in earnings of consolidated subsidiaries | 85.3 |  |  | 22.3 |  |  | — |  |  | (107.6 | ) |  | — |
Income (Loss) from Continued Operations | 41.6 |  |  | (25.3 | ) |  | 9.6 |  |  | (109.2 | ) |  | (83.3 | )
(Loss) Income from discontinued operations, net of tax | (1.8 | ) |  | 108.6 |  |  | 16.3 |  |  | — |  |  | 123.1 |
Net Income (Loss) | 39.8 |  |  | 83.3 |  |  | 25.9 |  |  | (109.2 | ) |  | 39.8 |
Total other comprehensive loss, net of tax | (6.9 | ) |  | (6.3 | ) |  | (7.2 | ) |  | 13.5 |  |  | (6.9 | )
Comprehensive Income | $ | 32.9 |  |  | $ | 77.0 |  |  | $ | 18.7 |  |  | $ | (95.7 | ) |  | $ | 32.9 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED COMBINED CONSOLIDATING INCOME AND COMPREHENSIVE INCOME STATEMENTS (in millions)
| Year Ended December 31, 2015
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Net Sales | $ | — |  |  | $ | 591.2 |  |  | $ | 266.4 |  |  | $ | (348.6 | ) |  | $ | 509.0 |
Cost of products sold | — |  |  | 338.8 |  |  | 261.0 |  |  | (348.6 | ) |  | 251.2 |
Gross Profit | — |  |  | 252.4 |  |  | 5.4 |  |  | — |  |  | 257.8 |
Research and development expenses | — |  |  | 27.6 |  |  | — |  |  | — |  |  | 27.6 |
Selling and general expenses | 30.6 |  |  | 274.4 |  |  | 44.7 |  |  | — |  |  | 349.7 |
Other (income) expense, net | (0.8 | ) |  | 26.9 |  |  | (9.9 | ) |  | — |  |  | 16.2 |
Operating Loss | (29.8 | ) |  | (76.5 | ) |  | (29.4 | ) |  | — |  |  | (135.7 | )
Interest income | 0.3 |  |  | — |  |  | 3.1 |  |  | (3.1 | ) |  | 0.3 |
Interest expense | (33.8 | ) |  | (2.1 | ) |  | (0.3 | ) |  | 3.1 |  |  | (33.1 | )
Loss Before Income Taxes | (63.3 | ) |  | (78.6 | ) |  | (26.6 | ) |  | — |  |  | (168.5 | )
Income tax benefit (provision) | 24.3 |  |  | 44.7 |  |  | (1.7 | ) |  | — |  |  | 67.3 |
Equity in (loss) earnings of consolidated subsidiaries | (389.5 | ) |  | 22.4 |  |  | — |  |  | 367.1 |  |  | — |
(Loss) Income from Continued Operations | (428.5 | ) |  | (11.5 | ) |  | (28.3 | ) |  | 367.1 |  |  | (101.2 | )
Income (Loss) from discontinued operations, net of tax | 2.2 |  |  | (366.4 | ) |  | 39.1 |  |  | — |  |  | (325.1 | )
Net (Loss) Income | (426.3 | ) |  | (377.9 | ) |  | 10.8 |  |  | 367.1 |  |  | (426.3 | )
Total other comprehensive loss, net of tax | — |  |  | (0.1 | ) |  | (24.0 | ) |  | — |  |  | (24.1 | )
Comprehensive (Loss) Income | $ | (426.3 | ) |  | $ | (378.0 | ) |  | $ | (13.2 | ) |  | $ | 367.1 |  |  | $ | (450.4 | )
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
Accounts receivable, net | 1.1 |  |  | 623.0 |  |  | 266.3 |  |  | (687.4 | ) |  | 203.0 |
Inventories | — |  |  | 76.0 |  |  | 15.1 |  |  | — |  |  | 91.1 |
Prepaid and other current assets | 0.6 |  |  | 11.7 |  |  | 2.1 |  |  | — |  |  | 14.4 |
Assets held for sale | 0.3 |  |  | 546.7 |  |  | 85.5 |  |  | — |  |  | 632.5 |
Total Current Assets | 116.5 |  |  | 1,273.4 |  |  | 458.2 |  |  | (687.4 | ) |  | 1,160.7 |
Property, Plant and Equipment, Net | — |  |  | 92.9 |  |  | 17.0 |  |  | — |  |  | 109.9 |
Investment in Consolidated Subsidiaries | 2,154.3 |  |  | 403.2 |  |  | — |  |  | (2,557.5 | ) |  | — |
Goodwill | — |  |  | 738.1 |  |  | 26.6 |  |  | — |  |  | 764.7 |
Other Intangible Assets, net | — |  |  | 139.5 |  |  | 9.4 |  |  | — |  |  | 148.9 |
Other Assets | 0.3 |  |  | 6.0 |  |  | 5.4 |  |  | — |  |  | 11.7 |
TOTAL ASSETS | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Current portion of long-term debt | $ | 39.8 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 39.8 |
Trade accounts payable | 454.0 |  |  | 347.0 |  |  | 49.8 |  |  | (679.6 | ) |  | 171.2 |
Accrued expenses | 11.6 |  |  | 113.9 |  |  | 27.4 |  |  | (8.0 | ) |  | 144.9 |
Liabilities held for sale | — |  |  | 7.8 |  |  | 26.1 |  |  | — |  |  | 33.9 |
Total Current Liabilities | 505.4 |  |  | 468.7 |  |  | 103.3 |  |  | (687.6 | ) |  | 389.8 |
Long-Term Debt | 541.1 |  |  | — |  |  | — |  |  | — |  |  | 541.1 |
Other Long-Term Liabilities | 9.2 |  |  | 36.1 |  |  | 4.3 |  |  | — |  |  | 49.6 |
Total Liabilities | 1,055.7 |  |  | 504.8 |  |  | 107.6 |  |  | (687.6 | ) |  | 980.5 |
Total Equity | 1,215.4 |  |  | 2,148.3 |  |  | 409.0 |  |  | (2,557.3 | ) |  | 1,215.4 |
TOTAL LIABILITIES AND EQUITY | $ | 2,271.1 |  |  | $ | 2,653.1 |  |  | $ | 516.6 |  |  | $ | (3,244.9 | ) |  | $ | 2,195.9 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS (in millions)
| As of December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
ASSETS |  |  |  |  |  |  |  |  |
Current Assets |  |  |  |  |  |  |  |  |
Cash and cash equivalents | $ | 54.2 |  |  | $ | 9.5 |  |  | $ | 50.0 |  |  | $ | — |  |  | $ | 113.7 |
Accounts receivable, net | 3.1 |  |  | 552.5 |  |  | 239.9 |  |  | (607.0 | ) |  | 188.5 |
Inventories | — |  |  | 69.2 |  |  | 11.5 |  |  | — |  |  | 80.7 |
Prepaid and other current assets | 5.0 |  |  | 10.1 |  |  | 1.8 |  |  | (0.3 | ) |  | 16.6 |
Assets held for sale | — |  |  | 162.3 |  |  | 31.7 |  |  | — |  |  | 194.0 |
Total Current Assets | 62.3 |  |  | 803.6 |  |  | 334.9 |  |  | (607.3 | ) |  | 593.5 |
Property, Plant and Equipment, Net | — |  |  | 96.7 |  |  | 12.6 |  |  | — |  |  | 109.3 |
Investment in Consolidated Subsidiaries | 2,029.5 |  |  | 328.7 |  |  | — |  |  | (2,358.2 | ) |  | — |
Goodwill | — |  |  | 736.1 |  |  | 26.2 |  |  | — |  |  | 762.3 |
Other Intangible Assets, net | — |  |  | 159.5 |  |  | 8.7 |  |  | — |  |  | 168.2 |
Other Assets | 0.7 |  |  | 7.7 |  |  | 3.2 |  |  | — |  |  | 11.6 |
Assets Held for Sale | 0.3 |  |  | 380.0 |  |  | 46.6 |  |  | — |  |  | 426.9 |
TOTAL ASSETS | $ | 2,092.8 |  |  | $ | 2,512.3 |  |  | $ | 432.2 |  |  | $ | (2,965.5 | ) |  | $ | 2,071.8 |
LIABILITIES AND EQUITY |  |  |  |  |  |  |  |  |
Current Liabilities |  |  |  |  |  |  |  |  |
Trade accounts payable | $ | 398.3 |  |  | $ | 325.9 |  |  | $ | 38.3 |  |  | $ | (601.9 | ) |  | $ | 160.6 |
Accrued expenses | 11.1 |  |  | 108.5 |  |  | 24.2 |  |  | (5.4 | ) |  | 138.4 |
Liabilities held for sale | — |  |  | 8.3 |  |  | 17.1 |  |  | — |  |  | 25.4 |
Total Current Liabilities | 409.4 |  |  | 442.7 |  |  | 79.6 |  |  | (607.3 | ) |  | 324.4 |
Long-Term Debt | 579.0 |  |  | — |  |  | — |  |  | — |  |  | 579.0 |
Other Long-Term Liabilities | 1.9 |  |  | 52.9 |  |  | 4.4 |  |  | — |  |  | 59.2 |
Liabilities Held for Sale | — |  |  | 1.5 |  |  | 5.2 |  |  | — |  |  | 6.7 |
Total Liabilities | 990.3 |  |  | 497.1 |  |  | 89.2 |  |  | (607.3 | ) |  | 969.3 |
Total Equity | 1,102.5 |  |  | 2,015.2 |  |  | 343.0 |  |  | (2,358.2 | ) |  | 1,102.5 |
TOTAL LIABILITIES AND EQUITY | $ | 2,092.8 |  |  | $ | 2,512.3 |  |  | $ | 432.2 |  |  | $ | (2,965.5 | ) |  | $ | 2,071.8 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2017
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (43.3 | ) |  | $ | 137.2 |  |  | $ | 50.3 |  |  | $ | — |  |  | $ | 144.2 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (32.4 | ) |  | (10.8 | ) |  | — |  |  | (43.2 | )
Proceeds from dispositions of property | — |  |  | 0.1 |  |  | — |  |  | — |  |  | 0.1 |
Intercompany contributions | — |  |  | (98.8 | ) |  | — |  |  | 98.8 |  |  | — |
Cash (Used in) Provided by Investing Activities | — |  |  | (131.1 | ) |  | (10.8 | ) |  | 98.8 |  |  | (43.1 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 101.4 |  |  | — |  |  | (2.6 | ) |  | (98.8 | ) |  | — |
Purchase of treasury stock | (2.5 | ) |  | — |  |  | — |  |  | — |  |  | (2.5 | )
Proceeds and excess tax benefits from the exercise of stock options | 4.7 |  |  | — |  |  | — |  |  | — |  |  | 4.7 |
Cash Provided by (Used in) Financing Activities | 103.6 |  |  | — |  |  | (2.6 | ) |  | (98.8 | ) |  | 2.2 |
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | 0.4 |  |  | 2.3 |  |  | — |  |  | 2.7 |
Increase in Cash and Cash Equivalents | 60.3 |  |  | 6.5 |  |  | 39.2 |  |  | — |  |  | 106.0 |
Cash and Cash Equivalents, Beginning of Period | 54.2 |  |  | 9.5 |  |  | 50.0 |  |  | — |  |  | 113.7 |
Cash and Cash Equivalents, End of Period | $ | 114.5 |  |  | $ | 16.0 |  |  | $ | 89.2 |  |  | $ | — |  |  | $ | 219.7 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2016
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (33.0 | ) |  | $ | 207.7 |  |  | $ | 15.8 |  |  | $ | (1.7 | ) |  | $ | 188.8 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (22.7 | ) |  | (6.4 | ) |  | — |  |  | (29.1 | )
Acquisition of business, net of cash acquired | (175.0 | ) |  | — |  |  | — |  |  | — |  |  | (175.0 | )
Proceeds from property dispositions | — |  |  | 3.2 |  |  | — |  |  | — |  |  | 3.2 |
Intercompany contributions | 0.5 |  |  | (177.9 | ) |  | 2.7 |  |  | 174.7 |  |  | — |
Cash (Used in) Provided by Investing Activities | (174.5 | ) |  | (197.4 | ) |  | (3.7 | ) |  | 174.7 |  |  | (200.9 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 170.8 |  |  | — |  |  | (0.3 | ) |  | (170.5 | ) |  | — |
Line of credit facility proceeds | 72.0 |  |  | — |  |  | — |  |  | — |  |  | 72.0 |
Line of credit facility repayments | (72.0 | ) |  | — |  |  | — |  |  | — |  |  | (72.0 | )
Debt issuance costs | (0.9 | ) |  | — |  |  | — |  |  | — |  |  | (0.9 | )
Purchase of treasury stock | (0.9 | ) |  | — |  |  | — |  |  | — |  |  | (0.9 | )
Proceeds and excess tax benefits from the exercise of stock options | 0.4 |  |  | — |  |  | — |  |  | — |  |  | 0.4 |
Cash Provided by (Used in) Financing Activities | 169.4 |  |  | — |  |  | (0.3 | ) |  | (170.5 | ) |  | (1.4 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | (0.8 | ) |  | (1.5 | ) |  | — |  |  | (2.3 | )
(Decrease) Increase in Cash and Cash Equivalents | (38.1 | ) |  | 9.5 |  |  | 10.3 |  |  | 2.5 |  |  | (15.8 | )
Cash and Cash Equivalents, Beginning of Period | 92.3 |  |  | — |  |  | 39.7 |  |  | (2.5 | ) |  | 129.5 |
Cash and Cash Equivalents, End of Period | $ | 54.2 |  |  | $ | 9.5 |  |  | $ | 50.0 |  |  | $ | — |  |  | $ | 113.7 |
HALYARD HEALTH, INC. AND SUBSIDIARIES CONDENSED COMBINED CONSOLIDATING STATEMENTS OF CASH FLOWS (in millions)
| Year Ended December 31, 2015
| Parent |  | Guarantor Subsidiaries |  | Non-Guarantor Subsidiaries |  | Eliminations |  | Consolidated
Operating Activities |  |  |  |  |  |  |  |  |
Cash (Used in) Provided by Operating Activities | $ | (44.7 | ) |  | $ | 110.5 |  |  | $ | 34.3 |  |  | $ | (2.5 | ) |  | $ | 97.6 |
Investing Activities |  |  |  |  |  |  |  |  |
Capital expenditures | — |  |  | (61.3 | ) |  | (9.1 | ) |  | — |  |  | (70.4 | )
Proceeds from property dispositions | — |  |  | — |  |  | 7.8 |  |  | — |  |  | 7.8 |
Intercompany contributions | 39.9 |  |  | (53.1 | ) |  | 1.3 |  |  | 11.9 |  |  | — |
Cash Provided by (Used in) Investing Activities | 39.9 |  |  | (114.4 | ) |  | — |  |  | 11.9 |  |  | (62.6 | )
Financing Activities |  |  |  |  |  |  |  |  |
Intercompany contributions | 46.5 |  |  | — |  |  | (34.6 | ) |  | (11.9 | ) |  | — |
Debt repayments | (51.0 | ) |  | — |  |  | — |  |  | — |  |  | (51.0 | )
Purchase of treasury stock | (1.0 | ) |  | — |  |  | — |  |  | — |  |  | (1.0 | )
Proceeds and excess tax benefits from the exercise of stock options | 1.4 |  |  | — |  |  | — |  |  | — |  |  | 1.4 |
Cash Used in Financing Activities | (4.1 | ) |  | — |  |  | (34.6 | ) |  | (11.9 | ) |  | (50.6 | )
Effect of Exchange Rate on Cash and Cash Equivalents | — |  |  | — |  |  | (3.9 | ) |  | — |  |  | (3.9 | )
Decrease in Cash and Cash Equivalents | (8.9 | ) |  | (3.9 | ) |  | (4.2 | ) |  | (2.5 | ) |  | (19.5 | )
Cash and Cash Equivalents, Beginning of Period | 101.2 |  |  | 3.9 |  |  | 43.9 |  |  | — |  |  | 149.0 |
Cash and Cash Equivalents, End of Period | $ | 92.3 |  |  | $ | — |  |  | $ | 39.7 |  |  | $ | (2.5 | ) |  | $ | 129.5 |

X
- References No definition available. + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.7-05(c)(Schedule II)) -URI http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=96868048&loc=d3e5283-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 2 -Subparagraph (SX 210.9-06) -URI http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section S99 -Paragraph 6 -Subparagraph (SX 210.5-04(c)(Schedule I)) -URI http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690 + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration